Ordenar

Buscar

01/12/2025 Biomarkers in Sarcoidosis: From Traditional Markers to Precision Medicine
Pascual, MB, Zapata-Huizi, JJ, Ramos, D, Francesqui, J, Alsina-Restoy, X, Hernández-González, F, Sellares, J. Biomarkers in Sarcoidosis: From Traditional Markers to Precision Medicine. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE. 2025; 46(06)DOI:10.1055/a-2741-2030. PMID:41213628. IF:2.700(Q2/5D).
01/12/2025 Perioperative pembrolizumab in early-stage non-small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup
Tsuboi, M, Wakelee, H, Spicer, JD, Gao, S, Liberman, M, Kato, T, Chen, KN, Dooms, C, Majem, M, Martinengo, GL, Bylicki, O, Abreu, DR, Halmos, B, Jones, DR, Chaft, J, Reck, M, Jense, E, Keller, SM, Samkari, A, Garassino, MC. Perioperative pembrolizumab in early-stage non-small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.10.607. PMID:. IF:65.400(Q1/1D).
01/12/2025 Impact of EBV status on the characteristics and prognosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients: Long-term experience from the GELTAMO group
Alós, DG, Sanchez, S, Dominguez, SR, Magnano, L, Barca, EG, Vicente, FD, Iacoboni, G, Manso, RG, Losada, CM, Huerga, S, Baumann, T, Izquierdo, AR, Bacelar, AG, Santaella, MP, Prieto, PG, De Villambrosia, SG, Bastos-Oreiro, M, Hernandez, AC, De Miguel, LB, Abellan, PF, Sturla, AL, Vidaller, PJP, Amutio, E, Toimil, FS, Pra, AM, Mico, M, De La Mano, EP, De La Cruz, B, Browne, S, Landwehr, M, Hernandez, I, Andreu, R, De La Cruz, J, Ubieto, AJ. Impact of EBV status on the characteristics and prognosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients: Long-term experience from the GELTAMO group. BLOOD. 2025; 146DOI:10.1182/blood-2025-472. PMID:. IF:23.100(Q1/1D).
01/12/2025 Frailty assessed by HCT-FS predicts survival and non-relapse mortality across hematologic disorders undergoing allo-HCT: A multicenter Study of 992 patients
Moya, TA, Gay, MQS, Pasic, I, Gonzalez, MB, Gómez, MA, Salinas, AS, Camacho, JS, Alvaro, VI, Abdallah-Lefdil, Z, Navascues, JC, Gambarte, LP, Fernandez-Luis, S, Vega, L, Villar, S, Murillo, PB, Esquirol, A, Garcia, II, Mussetti, A, Lavilla-Rubira, E, Lopez, J, Filafferro, S, Balsalobre, P, Miguel, LBD, Michelis, F, Viswabandya, A, Mattsson, J, Alibhai, S, Rovira, M, Kim, D, Balari, AS, Kumar, R. Frailty assessed by HCT-FS predicts survival and non-relapse mortality across hematologic disorders undergoing allo-HCT: A multicenter Study of 992 patients. BLOOD. 2025; 146DOI:10.1182/blood-2025-2652. PMID:. IF:23.100(Q1/1D).